TR200101174T2 - Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid. - Google Patents

Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.

Info

Publication number
TR200101174T2
TR200101174T2 TR2001/01174T TR200101174T TR200101174T2 TR 200101174 T2 TR200101174 T2 TR 200101174T2 TR 2001/01174 T TR2001/01174 T TR 2001/01174T TR 200101174 T TR200101174 T TR 200101174T TR 200101174 T2 TR200101174 T2 TR 200101174T2
Authority
TR
Turkey
Prior art keywords
metoclopramide
receptor agonists
migraine treatment
mammal
relates
Prior art date
Application number
TR2001/01174T
Other languages
English (en)
Turkish (tr)
Inventor
Harry Sands George
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200101174T2 publication Critical patent/TR200101174T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2001/01174T 1998-10-30 1999-10-18 Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid. TR200101174T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30

Publications (1)

Publication Number Publication Date
TR200101174T2 true TR200101174T2 (tr) 2001-10-22

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01174T TR200101174T2 (tr) 1998-10-30 1999-10-18 Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.

Country Status (34)

Country Link
US (2) US6255334B1 (fr)
EP (1) EP1126840A1 (fr)
JP (1) JP2002528497A (fr)
KR (1) KR20010089363A (fr)
CN (1) CN1325304A (fr)
AP (1) AP2001002129A0 (fr)
AR (1) AR019246A1 (fr)
AU (1) AU5994799A (fr)
BG (1) BG105534A (fr)
BR (1) BR9914901A (fr)
CA (1) CA2348543A1 (fr)
CO (1) CO4950530A1 (fr)
CZ (1) CZ20011468A3 (fr)
EA (1) EA200100284A1 (fr)
EE (1) EE200100243A (fr)
GT (1) GT199900189A (fr)
HK (1) HK1040929A1 (fr)
HR (1) HRP20010298A2 (fr)
HU (1) HUP0104696A3 (fr)
ID (1) ID28291A (fr)
IL (1) IL141957A0 (fr)
IS (1) IS5898A (fr)
MA (1) MA26702A1 (fr)
NO (1) NO20012013D0 (fr)
OA (1) OA11669A (fr)
PA (1) PA8484801A1 (fr)
PE (1) PE20001284A1 (fr)
PL (1) PL347541A1 (fr)
SK (1) SK5522001A3 (fr)
TN (1) TNSN99203A1 (fr)
TR (1) TR200101174T2 (fr)
TW (1) TW524692B (fr)
WO (1) WO2000025778A1 (fr)
ZA (1) ZA200103322B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
EP1392262A1 (fr) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6737043B2 (en) * 2001-05-24 2004-05-18 Alexza Molecula Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7078016B2 (en) 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
WO2002094242A1 (fr) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Administration de rizatriptan ou de zolmitriptan par voie d'inhalation
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
EP1503744A1 (fr) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Distribution de medicament a base d'amines par voie d'inhalation
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
CN101371843B (zh) 2002-11-26 2012-09-26 艾利斯达医药品公司 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2005123043A2 (fr) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
BRPI0607517A2 (pt) 2005-04-13 2009-09-08 Neuraxon Inc compostos de indol substituìdo, composição farmacêutica compreendendo o mesmo, método para tratar e uso do mesmo
WO2007118314A1 (fr) * 2006-04-13 2007-10-25 Neuraxon, Inc. Indoles 1,5- et 3,6-substitués à activité inhibitrice vis-à-vis de nos
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
AU2008323526A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
EP2219449A4 (fr) * 2007-11-16 2010-10-27 Univ Arizona State Procédés de traitement de la douleur viscérale
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
BR9710289A (pt) * 1996-07-11 1999-08-17 Farmarc Nederland Bv Composi-Æo farmac-utica contendo sal cido de adi-Æo de medicamento b sico
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
BR9914901A (pt) 2001-07-17
BG105534A (en) 2001-12-29
AR019246A1 (es) 2001-12-26
AU5994799A (en) 2000-05-22
HRP20010298A2 (en) 2002-06-30
CN1325304A (zh) 2001-12-05
IL141957A0 (en) 2002-03-10
AP2001002129A0 (en) 2001-06-30
HK1040929A1 (zh) 2002-06-28
MA26702A1 (fr) 2004-12-20
US6255334B1 (en) 2001-07-03
ZA200103322B (en) 2002-06-10
US20010020036A1 (en) 2001-09-06
WO2000025778A1 (fr) 2000-05-11
CO4950530A1 (es) 2000-09-01
OA11669A (en) 2005-01-05
EP1126840A1 (fr) 2001-08-29
TNSN99203A1 (fr) 2005-11-10
GT199900189A (es) 2001-04-21
EE200100243A (et) 2002-12-16
ID28291A (id) 2001-05-10
NO20012013L (no) 2001-04-24
HUP0104696A3 (en) 2003-05-28
SK5522001A3 (en) 2002-05-09
HUP0104696A2 (hu) 2002-05-29
KR20010089363A (ko) 2001-10-06
PE20001284A1 (es) 2000-11-22
NO20012013D0 (no) 2001-04-24
EA200100284A1 (ru) 2001-10-22
CZ20011468A3 (cs) 2002-04-17
JP2002528497A (ja) 2002-09-03
PA8484801A1 (es) 2000-09-29
TW524692B (en) 2003-03-21
PL347541A1 (en) 2002-04-08
CA2348543A1 (fr) 2000-05-11
IS5898A (is) 2001-03-16

Similar Documents

Publication Publication Date Title
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
TR200100054T2 (tr) Paroksetin metansülfonat
TR200102977T2 (tr) Yeni tedavi yöntemi.
PT957914E (pt) Formulacao de agonistas de 5-ht
CY1105481T1 (el) Συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη αλωπεκιας
GB9818916D0 (en) Use
HUP0103078A2 (hu) Készítmények és eljárások szürkehályog kezelésére
TR199802273T2 (xx) Fibrotik lezyonlar�n onar�lmas� ve �nlenmesi.
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
BR9814923A (pt) Método para tratamento de doença de alzheimer
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
BR9811094A (pt) Agente terapêutico para tumores linfáticos
HUP0101546A2 (hu) Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére
AU4130196A (en) Methods of treating migraine
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
ATE218881T1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
NO981222D0 (no) Ny kombinasjon av en <beta>-reseptorblokker og et opioid